Email
Print
Rheumatoid Arthritis Market By Product (Biologics, Non Biologics, Non-Steroidal Anti Inflammatory Drugs, Synthetic Disease Modifying Antirheumatic Drugs, Corticosteroids, Adalimumab, & Uric Acid Drugs), By Treatment (Synovectomy, Tendon Repair, Joint Fusion, & Total Joint Replacement), By Route of Administration (Oral, & Parental), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, & Online Pharmacy), By Geography - Global Opportunity Analysis & Industry Forecast, 2021-2026
Rheumatoid Arthritis Market Overview
Rheumatoid Arthritis market size is forecast to reach
$32.4 billion by 2026, growing at a CAGR of 5.2% during the forecast period
2021-2026. Rheumatoid Arthritis is an auto-immune disorder that affects joints
in the knee, and fingers with extra articular organs. Medications such as
methotrexate plays as an anti-inflammatory agent in controlling the progression
of rheumatoid arthritis and hormones in both genders play a role in either
preventing it. Symptoms include pain, tender, stiffness, and swelling of
joints. Disease modifying antirheumatic drugs is to mitigate the progression of
the disease and recent advancements with biosimilars is used to treat RA and
increase in approvals of the same by regulatory affairs. Increasing prevalence
of rheumatoid arthritis and increasing launch of novel therapeutic drugs are
the major factors driving the growth of the market. Favorable reimbursement
policies for high cost treatment products and improvements in diagnosis &
healthcare infrastructure is set to further enhance the overall market
development of the Rheumatoid Arthritis Market for the period 2021-2026.
Report Coverage
The report: “Rheumatoid Arthritis Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis
of the following segments of the Rheumatoid Arthritis Market.
By
Product: Biologics, Non Biologics, Non-Steroidal
Anti Inflammatory Drugs, Synthetic Disease Modifying Antirheumatic Drugs,
Corticosteroids, Adalimumab, and Uric Acid Drugs.
By
Treatment: Synovectomy,
Tendon Repair, Joint Fusion, and Total Joint Replacement.
By
Route of Administration: Oral, and Parental.
By
Distribution Channel: Hospital
Pharmacy, Retail Pharmacy, and Online Pharmacy.
By Geography: North
America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France,
Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India,
South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South
America (Brazil, Argentina, and Rest of South America), and Rest of the World
(Middle East, and Africa).
Key Takeaways
- North America dominated the Rheumatoid Arthritis Market in 2020 owing to increasing prevalence of rheumatoid arthritis and increasing awareness about the disorder. The Rheumatoid Arthritis Market scope for different regions will be provided in the final report.
- Rising awareness about arthritis along with its prevention among healthcare professional & patients and increasing efficiency of drugs in the treatment of rheumatoid arthritis are likely to aid the market growth of the Rheumatoid Arthritis Market report.
- Detailed analysis of the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Rheumatoid Arthritis Market report.
- Side effects associated with the consumption
of drugs and high cost associated with biologics & biosimilars is poised to
create hurdles for the Rheumatoid Arthritis Market.
Rheumatoid Arthritis Market Revenue Share, By Geography, 2020(%)
For More Details on This Report - Request for Sample
Rheumatoid Arthritis Market Segment Analysis – By Product
Synthetic Disease Modifying Antirheumatic Drugs held the
largest share in the Rheumatoid Arthritis Market in 2020 and is estimated to
grow at a CAGR 4.6% during the forecast period 2021-2026. This is attributed to
the rise in awareness related to the use of disease modifying antirheumatic
drugs and increasing prevalence of rheumatoid arthritis. Rise in obese and
overweight population is also increasing the demand of the drug.
Corticosteroids reduce immune system activity as it ease swelling, redness, and
allergic reactions. It also used to treat diseases like asthma. Non-steroidal anti-inflammatory
drugs cannot treat the disease alone and it needs to be taken along with other
rheumatoid arthritis medications. These are beneficial in mitigating symptoms
and also prevent the rate of joint damage. Corticosteroids are estimated to
register the highest CAGR over the period 2021-2026.
Rheumatoid Arthritis Market Segment Analysis – By Route of Administration
Oral held the largest share in the Rheumatoid Arthritis
Market in 2020 and is estimated to grow at a CAGR 5.7% during the forecast
period 2021-2026. This is attributed to the higher prevalence of rheumatoid arthritis
and it also offers several benefits such as safety, ease of absorption,
adaptability to different kinds of drugs, and no pain during administration
among others. Oral are estimated to register the highest CAGR over the period
2021-2026.
Rheumatoid Arthritis Market Segment Analysis – By Geography
North America dominated the Rheumatoid Arthritis Market
with a major share of 37.3% in 2020. This is attributed to the increasing
prevalence of rheumatoid arthritis and increasing awareness about the disorder.
Increasing healthcare spending, increasing demand for disease modifying
antirheumatic drugs along with the increasing public awareness toward use and
benefits of these drugs is increasing the growth of the market in this region.
However, Asia Pacific is estimated to grow at a higher CAGR
during the forecast period 2021-2026 owing to the increasing penetration of
rheumatoid arthritis treatment drugs, specially biologics, and increasing
healthcare infrastructure. Increasing awareness and undertaking of treatment of
rheumatoid arthritis is also increasing the growth of the market in this
region.
Rheumatoid Arthritis Market Drivers
Rising Awareness about Arthritis and its Prevention
Rising awareness about arthritis and its prevention is increasing
the growth of the Rheumatoid Arthritis Market. Rheumatoid Arthritis is a
disease that cause damage and joint pain throughout the body. It usually
happens on the both sides of the body. Though medications have improved
treatment options but it can still cause physical disabilities. According to
World Health Organization, the prevalence of rheumatoid arthritis varies between 0.3% and 1% and is
more common in women and in developed countries and about 1.3 million Americans
have rheumatoid arthritis. Thus,
increasing the growth of the Rheumatoid Arthritis Market during the forecast
period 2021-2026.
Increasing Demand for Disease Modifying Antirheumatic Drugs
Increasing demand for disease modifying antirheumatic drugs is
increasing the growth of the Rheumatoid Arthritis Market. Disease modifying
antirheumatic drugs treats alters the underlying diseases by reducing pain, stiffness,
and swelling over a period of weeks or months. Conventional disease modifying
antirheumatic drugs are slow acting and it responds well with the medications.
Biological therapies are newer drugs that target individual molecules and it
works more quickly than conventional disease modifying antirheumatic drugs. It
target a protein called tumor that increases inflammation and are often given
in combination with a conventional disease modifying antirheumatic drugs. Thus,
increasing the growth of the Rheumatoid Arthritis Market during the forecast
period 2021-2026.
Rheumatoid Arthritis Market Challenges
Side Effects Associated with the Consumption of Drugs and High Cost Associated with Biologics & Biosimilars
Some of the factors that are set to impede the growth of the
Rheumatoid Arthritis Market are side effects associated with the consumption of
drugs and high cost associated with biologics & biosimilars. High cost
associated with biological disease modifying antirheumatic drugs therapies and expiry
of patents of vital drugs is also set to hinder the growth of the market.
Rheumatoid Arthritis Market Landscape
Product launches, mergers and acquisitions, joint ventures, and
R&D activities are key strategies adopted by players in the Rheumatoid
Arthritis Market. In 2020, the Rheumatoid Arthritis Market share is
consolidated by the top ten players present in the market. Rheumatoid Arthritis
Market, top 10 companies are AbbVie Inc., Amgen Inc., Bristol, Eli Lily &
Company, Novartis, Pfizer Inc, UCB SA, Squibb Company, and Gilead Science Inc.
among others.
Acquisitions/Product Launches
- In December 2019, Amgen Inc. received the approval of the US Food and Drug Administration for Avsola, a biosimilar drug rheumatoid arthritis drug.
Relevant reports:
Report Code: HCR 0323
1. Rheumatoid Arthritis Market- Overview
1.1 Definitions and Scope
2. Rheumatoid Arthritis Market- Executive Summary
2.1 Market Revenue and Key Trends by Company
2.2 Key trends by Product
2.3 Key trends by Treatment
2.4 Key trends by Rout of Administration
2.5 Key trends by Distribution Channel
2.6 Key trends by Geography
3. Rheumatoid Arthritis Market– Comparative Analysis
3.1 Product Benchmarking – Key Companies
3.2 Financial Analysis – Key Companies
3.3 Market Value Split by Key Companies
3.4 Patent Analysis – Key Companies
3.5 Pricing Analysis
4. Rheumatoid Arthritis Market- Startup Companies Scenario Premium
4.1 Key Startup Company Analysis by
4.1.1 Investment
4.1.2 Revenue
4.1.3 Venture Capital and Funding Scenario
5. Rheumatoid Arthritis Market– Industry Market Entry Scenario Premium Premium
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case Studies of Successful Ventures
6. Rheumatoid Arthritis Market Forces
6.1 Market Drivers
6.2 Market Constraints/Challenges
6.3 Porters five force model
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes
7. Rheumatoid Arthritis Market– Strategic Analysis
7.1 Value Chain Analysis
7.2 Opportunities Analysis
7.3 Market Life Cycle
8. Rheumatoid Arthritis Market– By Product (Market Size –$Million/$Billion)
8.1 Biologics
8.2 Non Biologics
8.3 Non-Steroidal Anti Inflammatory Drugs
8.4 Synthetic Disease Modifying Antirheumatic Drugs
8.5 Corticosteroids
8.6 Adalimumab
8.7 Uric Acid Drugs
9. Rheumatoid Arthritis Market– By Treatment (Market Size –$Million/$Billion)
9.1 Synovectomy
9.2 Tendon Repair
9.3 Joint Fusion
9.4 Total Joint Replacement
10. Rheumatoid Arthritis Market– By Material (Market Size –$Million/$Billion)
10.1 Silicone
10.2 Polyvinyl Chloride
10.3 Others
11. Rheumatoid Arthritis Market– By Route of Administration (Market Size –$Million/$Billion)
11.1 Oral
11.2 Parental
12. Rheumatoid Arthritis Market– By Distribution Channel (Market Size –$Million/$Billion)
12.1 Hospital Pharmacy
12.2 Retail Pharmacy
12.3 Online Pharmacy
13. Rheumatoid Arthritis Market- By Geography(Market Size –$Million/$Billion)
13.1 North America
13.1.1 U.S.
13.1.2 Mexico
13.1.3 Canada
13.2 Europe
13.2.1 U.K.
13.2.2 France
13.2.3 Germany
13.2.4 Italy
13.2.5 Spain
13.2.6 Russia
13.2.7 Rest of Europe
13.3 Asia Pacific
13.3.1 China
13.3.2 India
13.3.3 Japan
13.3.4 South Korea
13.3.5 Australia & New Zealand
13.3.6 Rest of Asia Pacific
13.4 South America
13.4.1 Brazil
13.4.2 Argentina
13.4.3 Rest of South America
13.5 Rest of the World
13.5.1 Middle East
13.5.2 Africa
14. Rheumatoid Arthritis Market- Entropy
15. Rheumatoid Arthritis Market– Industry/Segment Competition Landscape Premium
15.1 Market Share Analysis
15.1.1 Global Market Share – Key Companies
15.1.2 Market Share by Region – Key companies
15.1.3 Market Share by Countries – Key Companies
15.1.4 Best Practices for Companies
16. Rheumatoid Arthritis Market– Key Company List by Country Premium Premium
17. Rheumatoid Arthritis Market Company Analysis
17.1 Company 1
17.2 Company 2
17.3 Company 3
17.4 Company 4
17.5 Company 5
17.6 Company 6
17.7 Company 7
17.8 Company 8
17.9 Company 9
17.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.
LIST OF TABLES
1.Global GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS Market 2019-2024 ($M)1.1 DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS Market 2019-2024 ($M) - Global Industry Research
1.2 NON-STEROIDAL ANTI- INFLAMMATORY DRUGS Market 2019-2024 ($M) - Global Industry Research
1.3 CORTICOSTEROIDS Market 2019-2024 ($M) - Global Industry Research
1.4 ANALGESICS Market 2019-2024 ($M) - Global Industry Research
2.Global GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION Market 2019-2024 ($M)
2.1 ORAL Market 2019-2024 ($M) - Global Industry Research
2.2 PARENTERAL Market 2019-2024 ($M) - Global Industry Research
3.Global GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS Market 2019-2024 (Volume/Units)
3.1 DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS Market 2019-2024 (Volume/Units) - Global Industry Research
3.2 NON-STEROIDAL ANTI- INFLAMMATORY DRUGS Market 2019-2024 (Volume/Units) - Global Industry Research
3.3 CORTICOSTEROIDS Market 2019-2024 (Volume/Units) - Global Industry Research
3.4 ANALGESICS Market 2019-2024 (Volume/Units) - Global Industry Research
4.Global GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION Market 2019-2024 (Volume/Units)
4.1 ORAL Market 2019-2024 (Volume/Units) - Global Industry Research
4.2 PARENTERAL Market 2019-2024 (Volume/Units) - Global Industry Research
5.North America GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS Market 2019-2024 ($M)
5.1 DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS Market 2019-2024 ($M) - Regional Industry Research
5.2 NON-STEROIDAL ANTI- INFLAMMATORY DRUGS Market 2019-2024 ($M) - Regional Industry Research
5.3 CORTICOSTEROIDS Market 2019-2024 ($M) - Regional Industry Research
5.4 ANALGESICS Market 2019-2024 ($M) - Regional Industry Research
6.North America GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION Market 2019-2024 ($M)
6.1 ORAL Market 2019-2024 ($M) - Regional Industry Research
6.2 PARENTERAL Market 2019-2024 ($M) - Regional Industry Research
7.South America GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS Market 2019-2024 ($M)
7.1 DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS Market 2019-2024 ($M) - Regional Industry Research
7.2 NON-STEROIDAL ANTI- INFLAMMATORY DRUGS Market 2019-2024 ($M) - Regional Industry Research
7.3 CORTICOSTEROIDS Market 2019-2024 ($M) - Regional Industry Research
7.4 ANALGESICS Market 2019-2024 ($M) - Regional Industry Research
8.South America GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION Market 2019-2024 ($M)
8.1 ORAL Market 2019-2024 ($M) - Regional Industry Research
8.2 PARENTERAL Market 2019-2024 ($M) - Regional Industry Research
9.Europe GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS Market 2019-2024 ($M)
9.1 DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS Market 2019-2024 ($M) - Regional Industry Research
9.2 NON-STEROIDAL ANTI- INFLAMMATORY DRUGS Market 2019-2024 ($M) - Regional Industry Research
9.3 CORTICOSTEROIDS Market 2019-2024 ($M) - Regional Industry Research
9.4 ANALGESICS Market 2019-2024 ($M) - Regional Industry Research
10.Europe GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION Market 2019-2024 ($M)
10.1 ORAL Market 2019-2024 ($M) - Regional Industry Research
10.2 PARENTERAL Market 2019-2024 ($M) - Regional Industry Research
11.APAC GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS Market 2019-2024 ($M)
11.1 DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS Market 2019-2024 ($M) - Regional Industry Research
11.2 NON-STEROIDAL ANTI- INFLAMMATORY DRUGS Market 2019-2024 ($M) - Regional Industry Research
11.3 CORTICOSTEROIDS Market 2019-2024 ($M) - Regional Industry Research
11.4 ANALGESICS Market 2019-2024 ($M) - Regional Industry Research
12.APAC GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION Market 2019-2024 ($M)
12.1 ORAL Market 2019-2024 ($M) - Regional Industry Research
12.2 PARENTERAL Market 2019-2024 ($M) - Regional Industry Research
13.MENA GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS Market 2019-2024 ($M)
13.1 DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS Market 2019-2024 ($M) - Regional Industry Research
13.2 NON-STEROIDAL ANTI- INFLAMMATORY DRUGS Market 2019-2024 ($M) - Regional Industry Research
13.3 CORTICOSTEROIDS Market 2019-2024 ($M) - Regional Industry Research
13.4 ANALGESICS Market 2019-2024 ($M) - Regional Industry Research
14.MENA GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION Market 2019-2024 ($M)
14.1 ORAL Market 2019-2024 ($M) - Regional Industry Research
14.2 PARENTERAL Market 2019-2024 ($M) - Regional Industry Research
LIST OF FIGURES
1.US Rheumatoid Arthritis Market Revenue, 2019-2024 ($M)2.Canada Rheumatoid Arthritis Market Revenue, 2019-2024 ($M)
3.Mexico Rheumatoid Arthritis Market Revenue, 2019-2024 ($M)
4.Brazil Rheumatoid Arthritis Market Revenue, 2019-2024 ($M)
5.Argentina Rheumatoid Arthritis Market Revenue, 2019-2024 ($M)
6.Peru Rheumatoid Arthritis Market Revenue, 2019-2024 ($M)
7.Colombia Rheumatoid Arthritis Market Revenue, 2019-2024 ($M)
8.Chile Rheumatoid Arthritis Market Revenue, 2019-2024 ($M)
9.Rest of South America Rheumatoid Arthritis Market Revenue, 2019-2024 ($M)
10.UK Rheumatoid Arthritis Market Revenue, 2019-2024 ($M)
11.Germany Rheumatoid Arthritis Market Revenue, 2019-2024 ($M)
12.France Rheumatoid Arthritis Market Revenue, 2019-2024 ($M)
13.Italy Rheumatoid Arthritis Market Revenue, 2019-2024 ($M)
14.Spain Rheumatoid Arthritis Market Revenue, 2019-2024 ($M)
15.Rest of Europe Rheumatoid Arthritis Market Revenue, 2019-2024 ($M)
16.China Rheumatoid Arthritis Market Revenue, 2019-2024 ($M)
17.India Rheumatoid Arthritis Market Revenue, 2019-2024 ($M)
18.Japan Rheumatoid Arthritis Market Revenue, 2019-2024 ($M)
19.South Korea Rheumatoid Arthritis Market Revenue, 2019-2024 ($M)
20.South Africa Rheumatoid Arthritis Market Revenue, 2019-2024 ($M)
21.North America Rheumatoid Arthritis By Application
22.South America Rheumatoid Arthritis By Application
23.Europe Rheumatoid Arthritis By Application
24.APAC Rheumatoid Arthritis By Application
25.MENA Rheumatoid Arthritis By Application
26.ABBVIE, Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.BIOGEN, INC., Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.BRISTOL-MYERS SQUIBB, Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.CELGENE CORPORATION, Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.CELLTRION INC., Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.JOHNSON JOHNSON, Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.MEDIMMUNE, LLC, Sales /Revenue, 2015-2018 ($Mn/$Bn)
33.MERCK CO., INC., Sales /Revenue, 2015-2018 ($Mn/$Bn)
34.NOVARTIS INTERNATIONAL AG, Sales /Revenue, 2015-2018 ($Mn/$Bn)
35.TAKEDA PHARMACEUTICAL COMPANY LTD., Sales /Revenue, 2015-2018 ($Mn/$Bn)